ExxPharma Therapeutics LLC and Halo Pharmaceutical Inc. Join Hands to Develop Products using Twin Screw Extrusion Technology
FREMONT,CA: Halo Pharmaceutical Inc. and ExxPharma Therapeutics LLC recently announced their collaboration in order to develop drugs for customers of Halo and ExxPharma by leveraging ExxPharma's innovative drug delivery systems and twin screw extrusion technology. ExxPharma is expected to be in charge of the technical development whereas Halo will handle the general responsibility of drug manufacturing and quality control at Halo's high-tech GMP-compliant manufacturing facility located in Whippany, NJ.
Twin screw extrusion comprises of a highly versatile as well as controlled precision manufacturing process that uses small amount mixing in order to boost efficiency, quality while reducing cost. This technology although, finds itself new to the Pharma domain, has garnered widespread acceptance with hot melt extrusion (HME), that ExxPharma have used previously to better the bioavailability of inadequately soluble drug substances.
"Collaborating with Halo allows us to serve our clients more efficiently using fully-integrated, cost-effective complementary services which encompass formulation as well as process feasibility studies, Phase I to Phase III clinical development and commercial production," said Isaac Ghebre-Sellassie, President, ExxPharma. "Halo has a remarkable track record of developing clinical trial material as well as commercially viable drug products for U.S. as well as European markets. This collaboration allows us to concurrently transfer analytical and manufacturing technologies from a research and development environment at ExxPharma to a GMP compliant manufacturing facility."
"We are excited about this collaboration with ExxPharma and it provides an alternative technology to our customers," said Lee Karras, CEO, Halo Pharmaceutical Inc. "Moreover, Isaac is a preeminent scientist in this field and his guidance can be a tremendous asset for our customers who face challenges with bioavailability or if they wish to pursue abuse deterrent technologies which HME can potentially provide," Karras added.
By Michael Cockrill, CIO, State of Washington
By Brett Shockley, SVP & CIO, Avaya
By Sven Gerjets, SVP-IT, DIRECTV
By Steve Moyer, VP of Storage Software Engineering, Micron...
By Michelle R. McKenna-Doyle, SVP and CIO, National Football...
By Patrick Hale, CIO, VITAS Healthcare
By Roman Trakhtenberg, CEO, Luxoft
By Julia Davis, SVP, CIO, Aflac
By Chris Westlake, VP & GM of Service,RK
By Pauly Comtois, VP DevOps, Hearst Business Media
By Yanni Charalambous, VP & CIO, Occidental Petroleum...
By Bob Brown, VP-Production & Operations, ONE World Sports
By Arthur Hu, SVP & CIO, Lenovo
By Ron Guerrier, CIO, Farmers Insurance Group, Inc.
By Scott Cardenas, CIO, City and County of Denver
By Kevin McCarron, Vice President Collaboration, Carousel...
By Marc Kermisch, VP & CIO, Red Wing Shoe Co.
By Christopher Frenz, AVP of Information Security,...
By Brian Drozdowicz, VP, Digital Services, Siemens...
By Les Ottolenghi, EVP and CIO, Caesars Entertainment